Drug delivery, biodistribution and anti-EGFR activity: theragnostic nanoparticles for simultaneous in vivo delivery of tyrosine kinase inhibitors and kinase activity biosensors-Reference-Cited by-同舟云学术

Drug delivery, biodistribution and anti-EGFR activity: theragnostic nanoparticles for simultaneous in vivo delivery of tyrosine kinase inhibitors and kinase activity biosensors

Published:2021 Issue:44 Volume:13 Page:18520-18535
ISSN:2040-3364
Container-title:Nanoscale
language:en
Short-container-title:Nanoscale

Author:

Bofinger Robin¹,Weitsman Gregory²^ORCID,Evans Rachel²³^ORCID,Glaser Matthias¹⁴,Sander Kerstin¹⁴^ORCID,Allan Helen¹^ORCID,Hochhauser Daniel³,Kalber Tammy L.⁵^ORCID,Årstad Erik¹⁴,Hailes Helen C.¹^ORCID,Ng Tony²³^ORCID,Tabor Alethea B.¹^ORCID

Affiliation:

1. Department of Chemistry, University College London, 20, Gordon Street, London WC1H 0AJ, UK

2. School of Cancer and Pharmaceutical Sciences, King's College London, London, SE1 1UL, UK

3. UCL Cancer Institute, Paul O'Gorman Building, University College London, London WC1E 6DD, UK

4. Centre for Radiopharmaceutical Chemistry, Kathleen Lonsdale Building, 5 Gower Place, London WC1E 6BS, UK

5. Centre for Advanced Biomedical Imaging, Paul O'Gorman Building, University College London, London WC1E 6DD, UK

Abstract

We report the development of targeted theragnostic lipid/peptide/DNA lipopolyplexes for delivery of both a tyrosine kinase inhibitor, and plasmid DNA coding for a biosensor. These are used to quantify EGFR inhibition in cancer cell lines in vivo.

Funder

Medical Research Council

Cancer Research UK

Engineering and Physical Sciences Research Council

Publisher

Royal Society of Chemistry (RSC)

Subject

General Materials Science

Link

http://pubs.rsc.org/en/content/articlepdf/2021/NR/D1NR02770K

Reference75 articles.

1. Novel theranostic agents for next-generation personalized medicine: small molecules, nanoparticles, and engineered mammalian cells